Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 9/20 | 0.57 |
| ▸ | WNT1 | P04628 | 1/20 | 0.49 |
| ▸ | CLK2 | P49760 | 1/20 | 0.49 |
| ▸ | CLK3 | P49761 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10315571 | 0.89 | HTR1A (0.57) | NPSR1HTR1AHTR1DHTR1B | |
| SCHEMBL3198046 | 0.88 | ACKR3 (0.52) | ACKR3HTR1AHTR1DHTR1B | |
| SCHEMBL402086 | 0.86 | ACKR3 (0.51) | ACKR3NPSR1HTR1AHTR1DHTR1B | |
| SCHEMBL398679 | 0.86 | ACKR3 (0.51) | ACKR3NPSR1HTR1AHTR1DHTR1B | |
| SCHEMBL402839 | 0.85 | WNT1 (0.48) | ACKR3WNT1CLK2CLK3DYRK1A | |
| SCHEMBL8242499 | 0.84 | ACKR3 (0.51) | ACKR3NPSR1HTR1AHTR1DHTR1B | |
| SCHEMBL401714 | 0.84 | ACKR3 (0.49) | ACKR3NPSR1HTR1AHTR1DHTR1B | |
| SCHEMBL14417396 | 0.80 | ACKR3 (0.46) | ACKR3HTR1AHTR1DHTR1B | |
| SCHEMBL3204594 | 0.80 | ACKR3 (0.47) | ACKR3NPSR1HTR1AHTR1DHTR1B | |
| SCHEMBL3200902 | 0.80 | ACKR3 (0.47) | ACKR3NPSR1HTR1AHTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035770-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170267638-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2017-09-21 | — | — | US | disclosed |
| US-9643925-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2017-05-09 | — | — | US | disclosed |
| US-20160115133-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2016-04-28 | — | — | US | disclosed |
| US-9150564-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150005296-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2015-01-01 | — | — | US | disclosed |
| US-8871768-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871769-B2 | Ureas and their use in the treatment of heart failure | CYTOKINETICS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140038983-A1 | UREAS AND THEIR USE IN THE TREATMENT OF HEART FAILURE | CYTOKINETICS, INCORPORATED (US) | 2014-02-06 | — | — | US | disclosed |
| US-8513257-B2 | Ureas and their use in the treatment of heart failure | CYTOKINETICS, INCORPORATED (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120172372-A1 | Ureas and Their Use in the Treatment of Heart Failure | CYTOKINETICS, INC. | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172372-A1 | Ureas and Their Use in the Treatment of Heart Failure | TNNI3, TNNT2, MYLK2 | ACKR3 4761/4885WNT1 3796/4885CLK2 2892/4885 |
| US-20170267638-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | ACKR3 4807/4885WNT1 3877/4885CLK2 3004/4885 |
| US-20140038983-A1 | UREAS AND THEIR USE IN THE TREATMENT OF HEART FAILURE | TNNI3, TNNT2, MYLK2 | ACKR3 4761/4885WNT1 3796/4885CLK2 2892/4885 |
| US-20150005296-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | ACKR3 4807/4885WNT1 3877/4885CLK2 3004/4885 |
| US-20160115133-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | ACKR3 4807/4885WNT1 3877/4885CLK2 3004/4885 |
| US-10035770-B2 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | ACKR3 4807/4885WNT1 3877/4885CLK2 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.